Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

被引：48
作者：
Thorpe, Michael [2 ]
Montalvao, Ana [3 ]
Pierdomenico, Francesca [1 ]
Moita, Filipa [1 ]
Almeida, Antonio [1 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Serv Hematol, Lisbon, Portugal
[2] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia
[3] Hosp JJ Fernandes, Unidade Local Saude Baixo Alentejo, Unidade Oncol Hematol, Beja, Portugal
来源：
LEUKEMIA RESEARCH | 2012年 / 36卷 / 08期
关键词：
Chronic myelomonocytic leukemia; Myelodysplasia; Hypomethylating agents; 5-Azacitidine; AZACITIDINE; EFFICACY; CMML;
D O I：
10.1016/j.leukres.2012.04.024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1071 / 1073
页数：3
相关论文
共 8 条
  • [1] Activity of Azacitidine in Chronic Myelomonocytic Leukemia
    Costa, Rubens
    Abdulhaq, Haifaa
    Haq, Bushra
    Shadduck, Richard K.
    Latsko, Joan
    Zenati, Mazen
    Atem, Folefac D.
    Rossetti, James M.
    Sahovic, Entezam A.
    Lister, John
    [J]. CANCER, 2011, 117 (12) : 2690 - 2696
  • [2] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Finelli, Carlo
    Giagounidis, Aristoteles
    Schoch, Robert
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Bennett, John M.
    Byrd, John
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    [J]. LANCET ONCOLOGY, 2009, 10 (03) : 223 - 232
  • [3] MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    Figueroa, Maria E.
    Skrabanek, Lucy
    Li, Yushan
    Jiemjit, Anchalee
    Fandy, Tamer E.
    Paietta, Elisabeth
    Fernandez, Hugo
    Tallman, Martin S.
    Greally, John M.
    Carraway, Hetty
    Licht, Jonathan D.
    Gore, Steven D.
    Melnick, Ari
    [J]. BLOOD, 2009, 114 (16) : 3448 - 3458
  • [4] Risk assessment in chronic myelomonocytic leukemia (CMML)
    Germing, U
    Kündgen, A
    Gattermann, N
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (07) : 1311 - 1318
  • [5] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Kantarjian, Hagop
    Oki, Yasuhiro
    Garcia-Manero, Guillermo
    Huang, Xuelin
    O'Brien, Susan
    Cortes, Jorge
    Faderl, Stefan
    Bueso-Ramos, Carlos
    Ravandi, Farhad
    Estrov, Zeev
    Ferrajoli, Alessandra
    Wierda, William
    Shan, Jianqin
    Davis, Jan
    Giles, Francis
    Saba, Hussain I.
    Issa, Jean-Pierre J.
    [J]. BLOOD, 2007, 109 (01) : 52 - 57
  • [6] TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia
    Perez, Cristina
    Martinez-Calle, Nicolas
    Ignacio Martin-Subero, Jose
    Segura, Victor
    Delabesse, Eric
    Fernandez-Mercado, Marta
    Garate, Leire
    Alvarez, Sara
    Rifon, Jose
    Varea, Sara
    Boultwood, Jacqueline
    Wainscoat, James S.
    Cruz Cigudosa, Juan
    Jose Calasanz, Maria
    Cross, Nicholas C. P.
    Prosper, Felipe
    Agirre, Xabier
    [J]. PLOS ONE, 2012, 7 (02):
  • [7] The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    Vardiman, James W.
    Thiele, Juergen
    Arber, Daniel A.
    Brunning, Richard D.
    Borowitz, Michael J.
    Porwit, Anna
    Harris, Nancy Lee
    Le Beau, Michelle M.
    Hellstrom-Lindberg, Eva
    Tefferi, Ayalew
    Bloomfield, Clara D.
    [J]. BLOOD, 2009, 114 (05) : 937 - 951
  • [8] Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
    Wijermans, P. W.
    Rueter, B.
    Baer, M. R.
    Slack, J. L.
    Saba, H. I.
    Luebbert, M.
    [J]. LEUKEMIA RESEARCH, 2008, 32 (04) : 587 - 591
1